Sector News

UK drug industry slams lack of critical R&D skills

November 11, 2015
Life sciences

Pharmaceutical companies are finding it difficult to recruit for high skilled roles in the UK because of a shallow pool of good quality candidates, raising concerns that the country’s standing in global research and development is in danger of being weakened.

The Association of the British Pharmaceutical Industry is warning that an ongoing skills shortage threatens to undermine medicines R&D as pharmas are forced to seek expertise abroad, stalling growth and investment in the sector.

According to its report, Bridging the skills gap in the biopharmaceutical industry, the most concerning skills cited by industry leaders fall within “interdisciplinary areas” involving mathematics and biology.

Nine out of 10 surveyed cited concern about quality and quantity of candidates for vacancies in critical and fast-moving areas such as bioinformatics, health informatics, statistics and data mining, while 90% said they are seeing poor communications and team-working skills in new recruits.

Also of note, the ABPI says long-standing issues in the number and quality of applicants in areas such as translational medicine, clinical pharmacology and veterinary and toxicological pathology, highlighted in its previous skills report in 2008, are re-emerging as areas of concern.

Multi-sector approach and investment
The report authors have called for multi-sector approach and co-investment from the industry and government to tackle what is “a complex set of issues”, including a focus on the education pathway, “from the school curriculum to post-graduate studies and more high-quality apprenticeships,” the ABPI noted.

“We absolutely need to work with government and health and education policy makers to understand how best to address these gaps and challenges, in order to secure the UK’s position in life sciences and ensure it remains able to compete globally for talent and investment,” said Malcolm Skingle, chair of the Association’s Academic Liaison Expert Network. “Only through collaboration and co-investment between all relevant organisations can we ensure that the UK sustains and grows a highly skilled workforce for our sector in the future.”

Last week a report from the House of Commons science and technology committee, released ahead of chancellor George Osborne’s spending review on November 25, warned that extra investment in the sector is crucial if the UK is to hold on to its status as a “science superpower”.

Source: Pharma Times

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”